Mary  Reumuth net worth and biography

Mary Reumuth Biography and Net Worth

CFO of KALA BIO
Ms. Reumuth has served as our Chief Financial Officer since July 2017, Senior Vice President, Finance from February 2017 to July 2017, our Vice President, Finance from December 2014 to February 2017, our Senior Director, Finance from February 2014 to December 2014, as our Corporate Controller from February 2014 to July 2017 and Treasurer since February 2014. Prior to joining us, Ms. Reumuth acted as an independent financial consultant from November 2012 to January 2014 and, prior to that, served as Corporate Controller for Enobia Pharma Corp., or Enobia, a global biopharmaceutical company acquired by Alexion Pharmaceuticals, Inc., from May 2011 to June 2012. Prior to Enobia, Ms. Reumuth served as Director of Finance at Verenium Corporation, or Verenium, a biotechnology company, from December 2007 to March 2011. From 2001 to 2007, Ms. Reumuth held a variety of finance and accounting positions at Genzyme Corporation, or Genzyme, (now a Sanofi Company), and ILEX Oncology, Inc., or ILEX (acquired by Genzyme). Prior to ILEX, Ms. Reumuth was an auditor at Ernst & Young LLP. Ms. Reumuth earned her Bachelor’s degree in Business Administration from Texas A&M University—Corpus Christi, and is a Certified Public Accountant.

What is Mary Reumuth's net worth?

The estimated net worth of Mary Reumuth is at least $385,196.80 as of June 26th, 2024. Ms. Reumuth owns 60,187 shares of KALA BIO stock worth more than $385,197 as of November 21st. This net worth estimate does not reflect any other investments that Ms. Reumuth may own. Learn More about Mary Reumuth's net worth.

How old is Mary Reumuth?

Ms. Reumuth is currently 49 years old. There are 5 older executives and no younger executives at KALA BIO. The oldest executive at KALA BIO is Dr. Kim Brazzell Ph.D., Head of R&D and Chief Medical Officer, who is 71 years old. Learn More on Mary Reumuth's age.

How do I contact Mary Reumuth?

The corporate mailing address for Ms. Reumuth and other KALA BIO executives is 490 ARSENAL WAY SUITE 120, WATERTOWN MA, 02472. KALA BIO can also be reached via phone at (781) 996-5252 and via email at [email protected]. Learn More on Mary Reumuth's contact information.

Has Mary Reumuth been buying or selling shares of KALA BIO?

Mary Reumuth has not been actively trading shares of KALA BIO within the last three months. Most recently, Mary Reumuth sold 4,163 shares of the business's stock in a transaction on Wednesday, June 26th. The shares were sold at an average price of $4.75, for a transaction totalling $19,774.25. Following the completion of the sale, the chief financial officer now directly owns 60,187 shares of the company's stock, valued at $285,888.25. Learn More on Mary Reumuth's trading history.

Who are KALA BIO's active insiders?

KALA BIO's insider roster includes Todd Bazemore (COO), Romulus Brazzell (Insider), Hongming Chen (Insider), Mark Iwicki (CEO), and Mary Reumuth (CFO). Learn More on KALA BIO's active insiders.

Are insiders buying or selling shares of KALA BIO?

In the last twelve months, insiders at the sold shares 8 times. They sold a total of 41,021 shares worth more than $221,381.84. The most recent insider tranaction occured on June, 26th when insider Todd Bazemore sold 4,653 shares worth more than $22,101.75. Insiders at KALA BIO own 8.3% of the company. Learn More about insider trades at KALA BIO.

Information on this page was last updated on 6/26/2024.

Mary Reumuth Insider Trading History at KALA BIO

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/26/2024Sell4,163$4.75$19,774.2560,187View SEC Filing Icon  
5/31/2024Sell1,786$6.09$10,876.7464,350View SEC Filing Icon  
1/4/2022Sell2,850$1.30$3,705.00View SEC Filing Icon  
See Full Table

Mary Reumuth Buying and Selling Activity at KALA BIO

This chart shows Mary Reumuth's buying and selling at KALA BIO by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

KALA BIO Company Overview

KALA BIO logo
KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.
Read More

Today's Range

Now: $6.40
Low: $6.10
High: $6.40

50 Day Range

MA: $6.05
Low: $5.11
High: $7.63

2 Week Range

Now: $6.40
Low: $4.21
High: $10.97

Volume

13,708 shs

Average Volume

82,677 shs

Market Capitalization

$29.50 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A